AIs vs Tamoxifen: Results of EBCTG Meta-Analyses

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

Based on 2 meta-analyses of nearly 20,000 HR+ early breast cancer patients, AIs are superior to tamoxifen in reducing recurrences, whether as initial monotherapy or given in a “switching” strategy (abstract 12).

Based on 2 meta-analyses of nearly 20,000 HR+ early breast cancer patients, AIs are superior to tamoxifen in reducing recurrences, whether as initial monotherapy or given in a “switching” strategy (abstract 12). As initial monotherapy, AIs reduced the risk of recurrence by 23% over tamoxifen; for patients who switched to AIs after 2–3 yr of tamoxifen, AIs reduced the risk by 29%, relative to those who continued on tamoxifen, James Ingle, MD, reported.

The study was based on data submitted to the Early Breast Cancer Trialists’ Collaborative Group from 6 major trials. In cohort 1 (n = 9,856), patients receiving endocrine monotherapy (tamoxifen or an AI alone for a total of 5 yr), recurrences were seen in 15.3% of AI users at 8 yr post-diagnosis, vs 19.2% of tamoxifen users (P < .00001).

Study Results

“Compared with tamoxifen, AI monotherapy was associated with a highly significant absolute gain of 2.9% at 5 yr and 3.9% at 8 yr of patients who remained free of breast cancer recurrence,” Dr. Ingle said. AI use was associated with a decrease in breast cancer mortality of 1.1% at 5 yr and 0.5% at 8 yr compared with tamoxifen but this was not statistically significant.

Cohort 2 (n = 9,015) involved patients who, aft er 2–3 yr of tamoxifen, were randomized to continue tamoxifen for a total of 5 yr or to switch to an AI to complete their 5 yr of adjuvant endocrine therapy. At 6 yr post-randomization, breast cancer recurred in 12.6% of those switched to an AI vs 16.1% of those who continued on tamoxifen. The overall comparison of time to recurrence was highly significant (P < .00001).

Breast cancer mortality was significantly reduced with the use of AIs in the switching cohort, yielding an absolute reduction of 0.7% at 3 yr and 1.6% at 6 yr from treatment divergence.

Patients saw the most differential benefit from AIs while still on therapy vs after discontinuation. “There is a change when patients go off therapy, but AIs are still better,” Dr. Ingle noted. “AI treatment duration is now a major question to be answered.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.